{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Number of unique patients who had a treatment related (possible, probable or definite) adverse event that was graded 3 or greater according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03.","groups":[{"description":"Patients receive palifosfamide IV over 30 minutes on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Palifosfamide)"}],"paramType":"NUMBER","populationDescription":"All patients who enrolled and received treatment.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Treatment Related Adverse Events Grade 3 or Higher","type":"SECONDARY","unitOfMeasure":"participants"}